Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M33.2Revenue $M0.3Net Margin (%)--Altman Z-Score13.0
Enterprise Value $M-8.3EPS $-2.8Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.6Pre-tax Margin (%)--Higher ROA y-yN
Price/Book0.810-y EBITDA Growth Rate %-49.7Quick Ratio32.0Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-45.2Current Ratio32.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-40.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-42.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M9.1ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ABIO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABIOFirst Eagle Investment 2010-03-31 Sold Out -0.01%$110.88 - $345.24
($133.7)
$ 3.67-97%Sold Out0
ABIOFirst Eagle Investment 2009-12-31 Reduce$94.5 - $181.44
($126.59)
$ 3.67-97%Reduce -27.96%9,817
ABIOFirst Eagle Investment 2009-09-30 Add0.01%$95.76 - $184.8
($146.13)
$ 3.67-97%Add 62.38%13,627
ABIOFirst Eagle Investment 2009-06-30 Sold Out -0.02%$108.36 - $564.9
($288.19)
$ 3.67-99%Sold Out0
ABIOFirst Eagle Investment 2009-06-30 Add$108.36 - $564.9
($288.19)
$ 3.67-99%Add 24.34%8,392
ABIOFirst Eagle Investment 2009-03-31 Buy 0.02%$163.8 - $275.86
($219.26)
$ 3.67-98%New holding6,749
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABIO is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ABIO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Keuer Thomas ACOO 2015-10-16Sell496$5.14-28.6view
Selby Brian L.VP, Finance 2015-09-18Sell476$6.23-41.09view
Ozeroff Christopher DavidS.V.P., General Counsel 2015-09-18Sell1,129$6.32-41.93view
Keuer Thomas ACOO 2015-09-18Sell680$6.33-42.02view
BRISTOW MICHAEL RSee Remarks 2015-03-02Sell111$34.79-89.45view
Selby Brian L.VP, Finance 2015-03-02Sell23$34.79-89.45view
mccormack riley10% Owner 2015-01-16Sell7,143$37.24-90.15view
mccormack riley10% Owner 2015-01-07Sell11,224$45.08-91.86view
Wheeler Patrick MCFO 2014-09-18Sell168$64.19-94.28view
BRISTOW MICHAEL RPresident and CEO 2014-09-18Sell283$63.7-94.24view

Quarterly/Annual Reports about ABIO:

    News about ABIO:

    Articles On GuruFocus.com
    ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Nov 15 2010 
    ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Aug 10 2010 
    ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) May 10 2010 
    ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Nov 16 2009 
    ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Aug 10 2009 
    ARCA biopharma Inc. Reports Operating Results (10-Q) May 15 2009 
    ARCA biopharma Inc. Reports Operating Results (10-Q) Feb 07 2009 

    More From Other Websites
    Genetic-AF Clinical Trial for Prevention of Atrial Fibrillation Enrolls 50th Patient Jan 12 2016
    ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 12 2016
    GENETIC-AF Clinical Trial for Prevention of Atrial Fibrillation Enrolls 50th Patient Jan 12 2016
    ARCA BIOPHARMA, INC. Financials Dec 08 2015
    Applying Lessons from KBIO Dec 08 2015
    2 Micro-Cap Opportunities in Atrial Fibrillation Nov 30 2015
    Biotechs Under 20 Dollars Poised to Breakout Nov 23 2015
    ARCA biopharma to Present at the 27th Annual Piper Jaffray Healthcare Conference Nov 19 2015
    2 Important Takeaways from ARCA Biopharma's Q3 Results Nov 18 2015
    ARCA biopharma Announces Third Quarter 2015 Financial Results and Provides Business Update Nov 12 2015
    ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 12 2015
    ARCA biopharma Announces Third Quarter 2015 Financial Results and Provides Business Update Nov 12 2015
    ARCA biopharma CEO Michael Bristow to Present in Two Sessions at the American Heart Associations... Nov 05 2015
    ARCA biopharma CEO Michael Bristow to Present in Two Sessions at the American Heart Association... Nov 05 2015
    4 Stocks Under $10 Making Big Up Moves on Big Volume Nov 04 2015
    Venrock’s Latest Pick Shows There Are More Biotech Opportunities to Explore Oct 20 2015
    Biotech Pullback: Look to Targeted Therapy Companies Oct 19 2015
    Biotechs take a beating Oct 06 2015
    ARCA biopharma (ABIO): Leveraging Genetic Targeting to Better Treat Cardiovascular Disease Sep 15 2015
    ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 09 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK